Cardiovascular Risk, Chronic Kidney Disease, Inflammation - Kansas City MO

Summary:

Phase 3 - interventional, randomized, parallel-group, double blinded, placebocontrolled,
Multi-Centre, Multi-National CVOT on CV outcomes in participants
with established ASCVD, CKD, and systemic inflammation.

Inclusion:
 eGFR > 15
 Evidence of Atherosclerotic Cardiovascular Disease (ASCVD)
o Coronary Heart Disease
 History of MI
 Coronary revascularization, cardiac catherization, or CT Coronary
Angiography
o Cerebrovascular Disease
 History of Stroke
 Symptomatic Peripheral Artery Disease (PAD)

Exclusion:
 Diagnosis of Human Immunodeficiency Virus (HIV).
 On chronic or intermittent hemodialysis or peritoneal dialysis.
 History of bone marrow or solid organ transplant or anticipated organ transplant
during the study.
 Use preventative systemic antibiotics, systemic antivirals, or systemic antifungals
 Use of systemic immunosuppressive drugs (both small molecules and biologics).
This is not a complete list of inclusion and exclusion criteria for this study.
 

Qualified Participants May Receive:

Sponsor will pay for:

• The cost of the study medicine,
• The tests and checks,
• The time spent by the study doctor and staff and use of the clinics.

Qualified Participants Payments:

• Qualified participants will be paid $60.00 for each completed study visits.
• You will not be paid for telephone visits. You
• will be paid quarterly.